The week in pharma: action, reaction and insight – week to November 28

By Barbara Obstoj-Cardwell. Editor

Important regulatory news last week included Otsuka gaining accelerated Food and Drug Administration approval for its Voyxact (sibeprenlimab) for immunoglobulin A nephrology, India’s Sun Pharma for its Unloxcyt and Swiss giant Novartis for its spinal muscular atrophy drug Itvisma. Also of note, the US Centers for Medicare and Medicaid reported savings achieved in a second round of price negotiations.

First B-cell modulator approved in IgAN